# Clinical Genomics Pathology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clinical-genomics-pathology

- Industry: Biotechnology
- Headquarters: Bridgewater, US
- Website: www.clinicalgenomics.com
- Total disclosed funding: $41M
- Latest round: Series B (Jun 1, 2018)
- Investors on record: 2

## About

Clinical Genomics Pathology, Inc. specializes in genomic testing and diagnostics, focusing on innovative solutions that enhance healthcare delivery and patient outcomes through advanced technological applications.Clinical Genomics Pathology, Inc., founded in 2006 in Bridgewater, US, provides genomic testing solutions. The company has not undergone significant pivots or changes. The founders, Katrina Anderson and Tim Schottler, have a history in the healthcare sector. They secured USD 26 mn in Series B funding in June 2018, raised from investors Moelis Capital Partners, which brings the total amount raised to USD 26 mn.The company offers a suite of innovative genomic products and services designed to address specific needs within the healthcare industry. Their core product line includes advanced testing solutions that enhance diagnostic accuracy and provide data analytics capabilities. These offerings are primarily targeted at healthcare providers, contributing to improved patient care and operational efficiency. The company has successfully deployed its products in key markets across North America and Europe, establishing a diverse customer base that includes both small clinics and large healthcare systems.The company's revenue model is structured around a combination of subscription-based and direct sales approaches in the healthcare sector. Clients typically engage in annual subscription agreements for access to genomic testing services, with pricing plans based on volume and service complexity. These structured transactions facilitate predictable revenue streams, allowing the company to maintain strong customer relationships through ongoing support and updates. Flagship products are priced to attract a wide range of healthcare clients while ensuring a balance between accessibility and value.Clinical Genomics Pathology, Inc. plans to expand its product offerings with new genomic testing solutions scheduled for launch in the upcoming quarters, enhancing their existing portfolio. The company aims to enter new markets, particularly in Asia and South America, by the end of 2023. The recent funding of USD 26 mn will support these initiatives, enabling the development of new products and the establishment of a presence in these targeted regions.

## Funding rounds

- Series B, Jun 1, 2018, $26M — Moelis Capital Partners
- Series A, Mar 23, 2016, $15M — OneVentures

## Investors

- OneVentures (https://capitalatlas.ai/funds/oneventures) — Series A
- Moelis Capital Partners (https://capitalatlas.ai/funds/moelis-capital-partners) — Series B